Biocon
Search results
Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.
Concord Biotech Share Price: Find the latest news on Concord Biotech Stock Price. Get all the information on Concord Biotech with historic price charts for NSE / BSE.
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.
Concord Biotech IPO bidding started from August 4, 2023 and ended on August 8, 2023. The allotment for Concord Biotech IPO was finalized on Friday, August 11, 2023. The shares got listed on BSE, NSE on August 18, 2023. Concord Biotech IPO price band is set at ₹705 to ₹741 per share.
Concord Biotech Limited (CBL) is an Indian biotechnology company headquartered in Ahmedabad. The company manufactures fermentation -based biopharmaceutical active pharmaceutical ingredients (APIs) sold worldwide.
Get the latest Concord Biotech Ltd (CONCORDBIO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded...
4 days ago · Concord Biotech Limited Stock Price Today, Live NSE Share Price: Get the latest Concord Biotech Limited news, company updates, quotes, tips, historical charts, 52 week high low, market performance financial reports and many more at NSE India.
May 29, 2024 · Pharma firm Concord Biotech's shares scaled eight percent in trade on May 29, after Kotak Institutional Equities upgraded the stock to 'add' as the brokerage sees further scope for margins to...
